Physician profile
Philip W Shaffer
NPI 1205188844
$2,880.62
in general payments reported to CMS, 2019-2025
25 companies · $84.79 in 2025
The $84.79 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $618 · 2020: $339 · 2021: $879 · 2022: $397 · 2023: $287 · 2024: $276 · 2025: $84.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $612 · Education: $35.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $611.91 |
| Education | $35.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $935.54 | 2019-2022 | |
| Lensar, INC. | $417.30 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $200.62 | 2023-2025 | Miebo, Vyzulta, Xiidra |
| Alcon Vision LLC | $196.49 | 2019-2025 | Rocklatan, Precision7 |
| Novartis Pharmaceuticals Corporation | $173.26 | 2019-2022 | |
| Glaukos Corporation | $136.11 | 2020-2022 | |
| Sun Pharmaceutical Industries INC. | $135.69 | 2023-2025 | Cequa |
| Biotissue Holdings INC. | $112.29 | 2019-2023 | |
| Abbvie INC. | $86.73 | 2022 | |
| Mallinckrodt Hospital Products INC. | $73.57 | 2023 | Acthar |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $69.28 | 2021 | |
| Dompe US, INC. | $44.20 | 2021-2022 | |
| Tarsus Pharmaceuticals, INC. | $43.66 | 2024 | Xdemvy |
| Lombart Brothers, INC. | $41.04 | 2019 | |
| Rxsight INC | $34.29 | 2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $26.34 | 2024 | Tepezza |
| Quidel Corporation | $21.28 | 2019 | |
| Sight Sciences, INC. | $20.95 | 2021 | |
| Shire North American Group INC | $20.45 | 2019 | |
| Oyster Point Pharma, INC. | $19.60 | 2023 | Tyrvaya |
| Harrow Eye, LLC | $17.01 | 2024 | Vevye |
| Coopervision INC. | $15.46 | 2025 | Misight Contact Lens |
| Lkc Technologies, INC. | $14.71 | 2024 | |
| Ocular Therapeutix, INC. | $12.49 | 2021 | |
| Eyevance Pharmaceuticals LLC | $12.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Shaffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.